Form 4: Provectus Biopharmaceuticals: Director Morris Acquires Convertible Preferred Stock

Director Jeffrey Allen Morris reports acquisition of Series D-1 Convertible Preferred Stock in Provectus Biopharmaceuticals.

Summary

• On August 12, 2024, Jeffrey Allen Morris, a director of Provectus Biopharmaceuticals, acquired 264,314 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share.
• Following the transaction, Morris directly owns 4,260,061 shares of Series D-1 Convertible Preferred Stock, which are convertible into 42,600,610 shares of Common Stock.
• Morris also directly owns 12,000,000 shares of Common Stock and indirectly owns 6,500,000 shares of Common Stock through an IRA.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports a transaction. The director's purchase could be seen as a positive signal, but without further context, it's difficult to gauge the overall impact.

Positives

• Director's acquisition of convertible preferred stock may signal confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates a change in beneficial ownership by a company director.

Stakeholder Impact

• The transaction could potentially impact shareholders' perception of the company, depending on how they interpret the director's increased stake.

Key Dates